Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003-2014.
Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003-2014.
复制标题
DOI：
10.1136/bmjopen-2014-007508
复制
发表时间：
2015-05-22
期刊：
影响因子：
2.9
通讯作者：
Yu R
中科院分区：
文献类型：
--
作者：
Huang P;Tan J;Ma W;Zheng H;Lu Y;Wang N;Peng Z;Yu R
报告病毒学和免疫学治疗失败率和风险因素的10年结果。前瞻性队列研究。公司地址位于深圳市2003年12月至2014年1月深圳市国家治疗数据库中的2172名HIV阳性成年人。根据中国国家治疗指南进行抗逆转录病毒治疗。病毒学和免疫学治疗失败率。在调查的3099例患者中，2172例（70.1%）被纳入研究。中位年龄为33岁; 78.2%为男性，51.8%通过异性接触感染。 中位随访时间为31个月（IQR，26-38）。 共有81例（3.7%）患者死亡，而292例（13.4%）和400例（18.4%）患者分别发生病毒学和免疫学失败。校正后的考克斯回归分析表明，基线病毒载量（HR=2.19，95% CI 1.52 - 4.48，基线病毒载量大于或等于1 000 000拷贝/mL的患者与小于10 000拷贝/mL的患者相比）和WHO分期（HR=4.16，95% CI 2.01 - 10.57，WHO IV期患者与I期患者相比）与病毒学失败显著相关。 免疫治疗失败的最大风险因素是低CD 4细胞计数（与CD 4细胞计数小于50个细胞/mm 3的患者相比，CD 4细胞计数为50-99个细胞/mm 3的患者HR=0.46，95% CI 0.32 - 0.66）和治疗开始时基线WHO分期较高（与I期患者相比，WHO IV期患者的HR=2.15，95% CI 1.38 - 3.34）。持续的病毒学和免疫学结果表明，患者对长期抗逆转录病毒治疗反应积极，死亡率低。这项为期10年的数据研究为该地区的临床医生和政策制定者提供了重要信息，因为他们开始评估和规划自己迅速扩大的方案的未来需求。
To report 10-year outcomes of virological and immunological treatment failure rates and risk factors. Prospective cohort study. Shenzhen, China. 2172 HIV-positive adults in the national treatment database of Shenzhen from December 2003 to January 2014. Antiretroviral therapy according to the Chinese national treatment guidelines. Virological and immunological treatment failure rates. Of the 3099 patients surveyed, 2172 (70.1%) were included in the study. The median age was 33 years; 78.2% were male and 51.8% were infected through heterosexual contact. The median follow-up time was 31 months (IQR, 26–38). A total of 81 (3.7%) patients died, whereas 292 (13.4%) and 400 (18.4%) patients experienced virological and immunological failures, respectively. Adjusted Cox regression analysis indicated that baseline viral load (HR=2.19, 95% CI 1.52 to 4.48 for patients with a baseline viral load greater than or equal to 1 000 000 copies/mL compared to those with less than 10 000 copies/mL) and WHO stage (HR=4.16, 95% CI 2.01 to 10.57 for patients in WHO stage IV compared with those in stage I) were significantly associated with virological failure. The strongest risk factors for immunological treatment failure were a low CD4 cell count (HR=0.46, 95% CI 0.32 to 0.66 for patients with CD4 cell counts of 50–99 cells/mm3 compared to those with less than 50 cells/mm3) and higher baseline WHO stage at treatment initiation (HR=2.15, 95% CI 1.38 to 3.34 for patients in WHO stage IV compared to those in stage I). Sustained virological and immunological outcomes show that patients have responded positively to long-term antiretroviral treatment with low mortality. This 10-year data study provides important information for clinicians and policymakers in the region as they begin to evaluate and plan for the future needs of their own rapidly expanding programmes.
登录
查看更多内容
影响因子：
7.7
作者：
Yin W;Hao Y;Sun X;Gong X;Li F;Li J;Rou K;Sullivan SG;Wang C;Cao X;Luo W;Wu Z
通讯作者：
Wu Z
DOI：
10.1080/09540121003615129
发表时间：
2010-01-01
影响因子：
1.7
作者：
Zhao, Yan;Sun, Xin;Zhang, Fujie
通讯作者：
Zhang, Fujie
影响因子：
11.8
作者：
Ivers, LC;Kendrick, D;Doucette, K
通讯作者：
Doucette, K
影响因子：
168.9
作者：
Gilks, Charles F.;Crowley, Siobhan;De Cock, Kevin
通讯作者：
De Cock, Kevin
DOI：
10.1097/qai.0b013e3181c7d717
发表时间：
2010-02
期刊：
Journal of acquired immune deficiency syndromes (1999)
影响因子：
--
作者：
Li N;Wang Z;Sun D;Zhu Q;Sun G;Yang W;Wang Q;Nie Y;Wu Z
通讯作者：
Wu Z